The United Kingdom and the United States have reached a landmark trade agreement that will ensure zero import taxes on British medicine products entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to increase expenditure on medicines through the public health system. This move secures that import taxes on these key products will stay at zero for a period of 36 months.
This development follows previous threats to hike import taxes on patented pharmaceutical imports, with figures floated as high as double the cost.
"This arrangement between the United Kingdom strengthens the international landscape for innovative medicines and establishes much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Economic Significance
Pharmaceuticals represent one of the UK's largest exports to the America, which is by far the biggest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to September, the UK sold medicines worth billions to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This agreement safeguards employment, increases funding and facilitates the UK to emerge as a worldwide center for medical research," a minister commented.
Key NHS Changes
The agreement involves several key commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double total health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at 15%. Previously, repayments exceeded 20%.
Broader Context
The pact comes amid a long-running row between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
These tensions were intensified by claims that US consumers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been directed toward projects in the United States.
The Science Minister stated that the NHS must spend more on treatments, noting that its spending on drugs had declined as a share of its resources over the past decade.
